Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Smallpox Vaccine · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Smallpox Vaccine | BIOLOGICAL | - |
| HIVAC-1e | BIOLOGICAL | - |
| gp160 Vaccine (MicroGeneSys) | BIOLOGICAL | - |
Inclusion Criteria Concurrent Medication: Allowed: * All drugs, medications, and therapy which, by virtue of direct pharmacologic action or possible drug interaction, could influence the intended effects of the study vaccine or mask its side effects may be concomitantly administered only by presc...
Top 20 of 28 competitors
Smallpox Vaccine is a monoclonal antibody being studied for use in HIV Infections. It is currently in Phase 1 clinical development as an investigational therapy. The drug is being evaluated in a completed Phase 1 trial that enrolled healthy volunteers and individuals with HIV Infections.
Smallpox Vaccine is being developed by Bristol-Myers Squibb Company, which trades under the ticker BMY. The company is conducting clinical research on this monoclonal antibody for the treatment of HIV Infections.
Smallpox Vaccine is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 1 trial has been completed, and the drug remains in early-stage clinical research for HIV Infections.
Smallpox Vaccine has one completed Phase 1 clinical trial, identified as NCT00002261. This study compared HIVAC-1e and Smallpox (Vaccinia) Vaccines in previously vaccinated and unvaccinated volunteers. The trial was conducted in the United States and enrolled participants aged 18 years and older.
Smallpox Vaccine is not the same as HIVAC-1e. In clinical trial NCT00002261, HIVAC-1e and Smallpox (Vaccinia) Vaccines were studied as separate investigational products. Smallpox Vaccine is a monoclonal antibody, while HIVAC-1e is a different vaccine candidate.